A6X Stock Chart & Stats
€0.21
<€0.01(1.32%)
At close: 4:00 PM EST
€0.21
<€0.01(1.32%)
Day’s Range― - ―
52-Week Range€0.07 - €0.29
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€12.76M
Enterprise Value€109.16
Total Cash (Recent Filing)€2.87M
Total Debt (Recent Filing)€595.00K
Price to Earnings (P/E)―
Beta-0.22
Next Earnings
Nov 26, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.25
Shares Outstanding67,729,120
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.30
Price to Book (P/B)2.33
Price to Sales (P/S)6.68
P/FCF Ratio-7.70
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.03
Revenue Forecast (FY)€2.91M
Bulls Say, Bears Say
Bulls Say
Low LeverageDebt of roughly 0.6m against 55.2m of equity leaves the company with modest leverage and assets largely equity-funded. This reduces near-term solvency pressure and preserves flexibility to fund regulatory, development, and commercial work.
IP-Led Business ModelAn IP-led model centered on phenylcapsaicin and aXiphen® can support multiple application areas, including animal nutrition and industrial or biological uses. Partner and distributor routes may extend commercialization without requiring large-scale in-house manufacturing.
Multiple Monetization RoutesThe ability to monetize the technology through both product sales and licensing or collaborations creates more than one commercial route. If regulatory access and customer adoption progress, this structure could broaden revenue opportunities across geographies and applications.
Bears Say
Revenue ContractionThe TTM revenue decline and volatile multi-year sales history indicate that commercial traction has not yet become consistent. Unstable revenue makes it harder to absorb fixed development costs, plan investment, and demonstrate a dependable path to scalable earnings.
Severe UnprofitabilityNegative gross profit and a net margin near -95% show that current sales do not cover the company’s cost base. Persistent losses weaken retained capital and make future profitability dependent on substantial improvement in pricing, volume, or operating economics.
Persistent Cash BurnRecurring negative operating and free cash flow means the business is consuming cash rather than funding itself. Continued burn increases reliance on external capital, limits financial flexibility, and raises the importance of achieving operating improvement before resources are depleted.
aXichem AB Class A News
A6X FAQ
What was aXichem AB Class A’s price range in the past 12 months?
aXichem AB Class A lowest stock price was €0.07 and its highest was €0.29 in the past 12 months.
What is aXichem AB Class A’s market cap?
aXichem AB Class A’s market cap is €12.76M.
When is aXichem AB Class A’s upcoming earnings report date?
aXichem AB Class A’s upcoming earnings report date is Nov 26, 2026 which is in 56 days.
How were aXichem AB Class A’s earnings last quarter?
aXichem AB Class A released its earnings results on Aug 27, 2026. The company reported -€0.018 earnings per share for the quarter, missing the consensus estimate of -€0.013 by -€0.005.
Is aXichem AB Class A overvalued?
According to Wall Street analysts aXichem AB Class A’s price is currently Overvalued.
Does aXichem AB Class A pay dividends?
aXichem AB Class A does not currently pay dividends.
What is aXichem AB Class A’s EPS estimate?
aXichem AB Class A’s EPS estimate is >-0.01.
How many shares outstanding does aXichem AB Class A have?
aXichem AB Class A has 67,729,120 shares outstanding.
What happened to aXichem AB Class A’s price movement after its last earnings report?
aXichem AB Class A reported an EPS of -€0.018 in its last earnings report, missing expectations of -€0.013. Following the earnings report the stock price went up 2.538%.
Which hedge fund is a major shareholder of aXichem AB Class A?
Currently, no hedge funds are holding shares in DE:A6X
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
aXichem AB Class A
aXichem AB is a biotechnology firm, established in 2007 and headquartered in Malmö, Sweden, that specializes in creating natural analogue compounds. The company offers aXivite, a capsaicin analogue solution designed for various dietary health applications. Another key product, aXiphen-bio, functions as a biological repellent, providing antifouling protection for marine vessels and installations, and managing pests in agriculture, forestry, and for safeguarding cable infrastructure both within buildings and underground. Additionally, aXiphen-feed is developed to boost the health of poultry, including chickens and hens, as well as swine, such as pigs and piglets.
Technical Analysis
Hexpol AB
―
Nexam Chemical Holding AB
―
Polygiene AB
―
OrganoClick AB
―
Photocat A/S
―